- Reports Q2 (Jun) earnings of $0.86 per share, excluding non-recurring items, $0.12 better than the Capital IQ Consensus of $0.74; revenues rose 25.3% year/year to $920.9 mln vs the $863.91 mln Capital IQ Consensus.
- Co reaffirms guidance for FY16, sees EPS of $4.50-4.80, excluding non-recurring items, vs. $4.54 Capital IQ Consensus Estimate; sees FY16 revs of $3.87-4.03 bln vs. $3.93 bln Capital IQ Consensus Estimate.
08-Aug-16 16:47 ET
Endo Intl sees Q3 EPS of $0.77-0.82 vs $1.08 Capital IQ Consensus Estimate; sees revs $830-870 mln vs $952.29 mln Capital IQ Consensus Estimate
Courtesy of Briefing.com
ENDP reported last night and then guided the next quarter down a few minutes later. In spite of the guidance ENDP is up 2 bucks this morning, which shows you just how oversold ENDP was.
Targets are 25 and then 35. These are resistance levels, not arbitrary sell points.
For those who are willing to hold ENDP could get back to $63.50 in 12 to 18 months.